Appointment of adviser

Immupharma PLC
15 February 2007


For Immediate Release                                           15 February 2007


                                 ImmuPharma plc

                             Appointment of adviser

ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug
discovery and development company ImmuPharma plc is pleased to announce the
appointment of Teather & Greenwood Limited as nominated adviser and broker. The
appointment is with immediate effect.

Dawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc as
joint financial adviser.

For further information please contact:

ImmuPharma PLC:
Richard Warr, Chairman                                + 44 20 7152 4080
Dimitri Dimitriou, Chief Executive
Officer

Buchanan Communications                               + 44 20 7466 5000
Lisa Baderoon / Rebecca Skye
Dietrich

Notes to Editors:
About ImmuPharma

ImmuPharma PLC is a drug discovery and development company headquartered in
London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has
research operations in France (ImmuPharma (France) SA) and Switzerland
(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,
largely based on peptide therapeutics, to treat serious medical conditions such
as autoimmune diseases characterised by:


*   blockbuster potential in niche markets

*   low promotional costs in few specialised physicians and centres and

*   lower risk of drug development and lower development costs


ImmuPharma is a currently developing drug candidates for three different medical
conditions, each of which would represent a significant breakthrough in its
field. The furthest advanced drug candidate targets Lupus, a disease for which
there is currently no cure or specific treatment. The other two address moderate
to severe pain (such as that experienced by cancer sufferers and post-operative
patients), and MRSA and similar severe hospital-acquired resistant infections.






                      This information is provided by RNS
            The company news service from the London Stock Exchange